Stability of lectin binding properties expressed by human bladder carcinoma cell lines passaged in vitro or in nude mice
โ Scribed by Russell, P. J. ;Wotherspoon, J. ;Jelbart, M. ;Philips, J. ;Raghavan, D.
- Book ID
- 104701511
- Publisher
- Springer
- Year
- 1988
- Tongue
- English
- Weight
- 749 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
โฆ Synopsis
Binding of a panel of lectins by sublines of two human bladder carcinoma cell lines, UCRU-BL-17 CL and UCRU-BL-13 CL, assessed flow cytometrically following passage of the cells in vitro and in nude mice, was compared with that of human leukaemic cell lines, K562 and HL60, and found to be different. Marked glycosylation of sublines of both bladder cancer cell lines was found compared with normal human bladder transitional epithelium (assessed cytochemically). Neuraminidase pretreatment increased the binding of some lectins indicating that some galactose and N-acetylgalactosamine residues were sialylated. Lectin binding by UCRU-BL-17 CL sublines was remarkably constant on prolonged passage in vitro even though the lines underwent changes in physical characteristics and ploidy when grown in nude mice. This suggests that glycosylation of the tumour cell surface may represent an intrinsic feature of this bladder tumour.
๐ SIMILAR VOLUMES
## Abstract CD44 core and splice variant exon expression was investigated in the stratified transitional epithelium of the urinary tract and in normal and malignant bladder epithelial cell lines __in vitro.__ Antibodies against core CD44 epitopes and splice exon variants v3, v4/5, v5 and v6 showed
Two sublines were derived from a human bladder carcinoma continuous cell line (RTI 12-P), one by exposure to fractionated X-irradiation (RTI IZ-DXRa) and the other by continuous exposure to cisplatin (RT 112-CP). RTI I2-DXR8 cells were I .6to 2-fold more sensitive to cisplatin and 2 analogues, carbo
We have examined the anti-tumor effect in nude mice caused by human pancreatic cancer cells (AsPC-1) modified to secrete IL-2 or IL-4. Loss of tumorigenicity of cytokineproducing, but not wild-type, cells was observed despite their unaltered in vitro proliferation rates; and these anti-tumor effects